Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
Novo shares fell as much as 7% on Monday after the company laid out new growth ambitions to revive its fortunes in the booming obesity drug market. The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer. The company said it aims to launch more than five…
